14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
AMSF vs ADUS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ADUS Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–5 Matrix Metrics)
ADUS Overall Winner
6-Pillar Tally: AMSF 2 – 4 ADUS
Matrix Metrics: AMSF 5 – 5 ADUS
As of Nov 20, 2026, Addus HomeCare Corp. (ADUS) is the stronger overall head-to-head candidate over AMERISAFE, Inc. (AMSF) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). AMSF carries a Unified Composite Score of 55.6/100 (HOLD) at $18.87 (10.1x Forward P/E, 15.0% operating margin), whereas ADUS carries 59.0/100 (HOLD) at $122.50 (16.1x Forward P/E, 10.4% operating margin).
Technical & Structure Timing Caution: AMSF is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 22.9); meanwhile ADUS trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 51.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AMSF vs ADUS. Trailing 12-month operating profitability (AMSF 15.0% vs ADUS 10.4%) and valuation multiples (AMSF 10.1x vs ADUS 16.1x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Insurance - Specialty value chain with $350.3M market capitalization and 15.0% operating margin.
OpEx & R&D Reinvestment10.5% of Rev ($35M)
90D Engineering Disclosures0 Published
ADUS Moat ProfileCyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $2.3B market capitalization and 10.4% operating margin.
OpEx & R&D Reinvestment21.9% of Rev ($329M)
90D Engineering Disclosures0 Published
Investor FAQ AMSF vs ADUS Key Questions & Quantitative Answers
As of Nov 20, 2026, Addus HomeCare Corp. (ADUS) is the stronger overall head-to-head candidate over AMERISAFE, Inc. (AMSF) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). AMSF carries a Unified Composite Score of 55.6/100 (HOLD) at $18.87 (10.1x Forward P/E, 15.0% operating margin), whereas ADUS carries 59.0/100 (HOLD) at $122.50 (16.1x Forward P/E, 10.4% operating margin). Technical & Structure Timing Caution: AMSF is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 22.9); meanwhile ADUS trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 51.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ADUS leads the Growth & Scale pillar: AMSF posts -2.6% YoY revenue growth and -46.0% YoY earnings growth on $333M TTM revenue (25.5% gross margin, 15.0% operating margin), compared with ADUS at +7.0% YoY revenue growth and +24.2% YoY earnings growth on $1.50B TTM revenue (32.3% gross margin, 10.4% operating margin). On trailing 12-month operating scale, AMSF generates $333M in USD-normalized revenue versus $1.50B for ADUS. In operating R&D and SG&A reinvestment, AMSF deploys 10.5% of Rev ($35M) (0 90-day corporate R&D disclosures) versus 21.9% of Rev ($329M) (0 disclosures) for ADUS.
AMSF screens cheaper on headline valuation multiples. AMSF trades at 10.1x Forward P/E, 8.8x Trailing P/E, 1.81x PEG, and 1.1x EV/Revenue (3.7% FCF margin), whereas ADUS trades at 16.1x Forward P/E, 20.1x Trailing P/E, 1.05x PEG, and 1.5x EV/Revenue (11.5% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AMSF (15.8% ROE) versus ADUS (10.0% ROE) capital efficiency.
In options market volatility and institutional positioning, AMSF carries 26.2% implied volatility (15th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (-0.21β · 44% Vol realized risk). By comparison, ADUS carries 21.9% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.07β · 21% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.